About

In addition to the Diallertest^® product range, the VIASKIN^® technology also has the following key applications:

• Allergy desensitisation
  Peanut allergy desensitisation studies are in pre-clinical trials.
• Epicutaneous Administration of Vaccines
  DBV Technologies is developing prophylactic vaccination programmes for Hepatitis A and B, Meningitis, Typhoid, flu, and Shigella, as well as therapeutic oncology vaccines. Preclinical trials have delivered encouraging results for different vaccination models, such as mass immunization (bio-defence, oncology).
• Epidermal treatment applications or cosmaceuticals
  DBV Technologies is currently in discussions with large global cosmetics companies with regards to the use of VIASKIN^® technology for cosmaceutical epidermal hydration therapies.

Company Information

Corporate factsheet
Corporate Film
Diallertest^® film part 1 Diallertest^® film part 2

About VIASKIN^® Technology

About Diallertest^® product range